Sign in

CIK 0001652130 · Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
364785571
Phone
857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$417,899
in 3 filings, $395K under 10b5-1 plans

Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. LEONARD JOHN M −$395K President and CEO sold 3% of stake
  2. Dube Michael P −$23K VP, Chief Accounting Officer sold 3% of stake

Reading 7 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-01-05 Cohen Fred E Director Purchase +150,000 $9.35 $1.4M 207,453
2025-08-20 CHASE WILLIAM J Director Purchase +100,000 $10.03 $1.0M 134,693
2019-03-06 SCHIERMEIER ANDREW EVP, Dev and Corp Strategy Purchase +3,250 $16.00 $52K 3,250
2019-03-06 SCHIERMEIER ANDREW EVP, Dev and Corp Strategy Purchase +4,250 $15.50 $66K 7,500
2016-05-11 ORBIMED ADVISORS LLC Director Purchase +191,466 $18.00 $3.4M 2,603,646
2016-05-11 ORBIMED ADVISORS LLC Director Purchase +58,534 $18.00 $1.1M 2,662,180
2016-05-11 Temasek Holdings (Private) Ltd 10% owner Purchase +300,000 $18.00 $5.4M 790,527
2016-05-11 BAKER BROS. ADVISORS LP Former 10% owner Purchase +20,469 $18.00 $368K 85,906
2016-05-11 BAKER BROS. ADVISORS LP Former 10% owner Purchase +179,531 $18.00 $3.2M 976,214
2016-05-11 Novartis Institutes for BioMedical Research, Inc. 10% owner Purchase +277,777 $18.00 $5.0M 5,573,658

Page 1 of 1 · 10 trades